Glycotope received regulatory approval for glycooptimized and fully human glycosylated antibody CetuGEX
13-Aug-2010 -
Glycotope GmbH, has received regulatory approval by German and Italian regulatory authorities for a Phase I study of Glycotope's next generation antibody CetuGEX (GT-MAB 5.2-GEX) for the treatment of various solid
cancers.
“For Glycotope, the approval of CetuGEX, our 2nd antibody in the clinic, ...
bioavailability
cell lines
Glycosylation
+3